November 8, 2015 | Israeli bio-med company Vascular Biogenics raised $15 million following the closure of its stock offering of 2,500,000 ordinary shares at $6.00 per share. The company intends to use the net proceeds from the offering for the advancement of clinical programs, and for working capital. Founded in 2000 by CEO Prof. Dror Harats, Vascular Biogenics is a late-stage clinical bio-pharmaceutical company focused on the discovery, development and commercialization of gene-based treatments for cancer, including their lead drug, VB-111 that is being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024

TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024

Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024

BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments